REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions > In An Organic Compound > Attached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative Thereof Attached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative ThereofAttached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative Thereof patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070189966 - Diagnostic agents for pancreatic exocrine function The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host ... 08/02/07 - 20070178045 - Cyclopeptide derivatives with anti-integrin activity Formula (I) compounds are described c(R1-Arg-Gly-Asp-R2) where the meanings of the various groups are as described here below, which are integrin inhibitors, and particularly inhibitors of integrins of the α,β3 and α,β5 family, and therefore are useful as medicaments, particularly for the treatment of the diseases underlying abnormal angiogenesis, such ... 07/12/07 - 20070160535 - Vexotoxin pharmaceutical compositions and medical treatments therewith Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be ... 07/12/07 - 20070160534 - Methods and compositions for prolonging elimination half-times of bioactive compounds Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent The hybrid molecules of the invention may be prepared ... 07/12/07 - 20070160533 - Pharmacokinetic modulation and compositions for modified fn3 polypeptides The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides. ... 07/12/07 - 20070160532 - Composition for medical use having improved water-solubility of peptide and metal-labeling efficiency and preparation for medical use comprising metal-labeled peptide By preliminarily dissolving a basic organic compound in an aqueous solvent in which a peptide usable in metal-labeling is to be dissolved, the solubility of the peptide is improved and thus metal-labeling can be carried out without heating. A composition for medical use containing a peptide usable in metal-labeling and ... 07/05/07 - 20070154392 - Treatment process using somatostatin analogues wherein Z is optionally present or absent and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N4-chelators, desferrioxamine, NXSY-chelators, tyrosine for halogenation, a fluorescent dye, and biotin; L is optionally present or absent and when present is a linker ... 06/28/07 - 20070148092 - Compositions and methods for imaging pain and stress in vivo Briefly described, embodiments of the present disclosure relate to methods and compositions for imaging pain and/or stress in a subject and methods and compositions for treating associated conditions. In particular, the present disclosure relates to the use of labeled compounds to provide objective diagnosis of pain and/or stress, for imaging ... 06/28/07 - 20070148091 - Peptides and compounds that bind to a receptor Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide ... 06/28/07 - 20070148090 - Per (3,6-anhydro) cyclodextrin derivatives, preparation thereof and use thereof for transporting metal elements to biological targets or for decontaminating biological targets of fluids in which: at least one of the values R1 represents a radical chosen from peptides, proteins, lipids, oligonucleotides or polynucleotides, oligosaccharides or polysaccharides, and biopolymers, and the other possible values R1, which may be identical or different, represent a group chosen from OH, OR3, OM, SH, SR3, OCOR3, NH2, NHR2,NR3R4, ... 06/21/07 - 20070140967 - Agents and methods for analyzing protein interactions Agents and methods for qualitative and quantitative analysis a protein complex or protein complexes using isotope-labeled symmetrical bifunctional crosslinkers and mass spectrometry are provided. Targeting moieties, cell permeability moieties, or affinity moieties, may be appended to the bifunctional crosslinkers. The isotope-labeled symmetrical bifunctional crosslinkers may be used in a kit ... 06/14/07 - 20070134155 - Pharmaceutical compounds The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias ... 05/24/07 - 20070116644 - Cobalamin conjugates useful as imaging and therapeutic agents The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis. ... 04/26/07 - 20070092444 - Inhibition of inward sodium currents in cancer Described is a constitutive inward Na+ currents found in a variety of human cancers. The constitutive inward Na+ current plays a role in increased cellular proliferation, cellular migration and volume regulation. The inward current is mediated, at least in part, by AISC-containing Na+ channels. In addition, an inhibitor of the ... 03/29/07 - 20070071678 - Electrical initiation system An apparatus and method of using electrically initiated primer systems that rely on vaporizing a thin metallic film which is either coated on a non-conductive insulator component or is a malleable thin film or strip secured to the inner surface of a primer cup assembly to ignite an environmentally safe ... 03/29/07 - 20070071677 - Non-toxic membrane-translocating peptides Compositions for transport across a biological membrane include a membrane-translocating LMWP peptide and a cargo molecule. Methods for transporting a cargo molecule across a biological membrane are also described. ... 03/22/07 - 20070065362 - Gastrin receptor-avid peptide conjugates A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject ... 03/08/07 - 20070053838 - Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in ... 03/08/07 - 20070053837 - Radiopharmaceuticals for cancer diagnosis and treatment Radionuclide labelled conjugates based on substance P and analogues thereof with the chelator (DOTAGA) (1-(1-rarboxy-3-carboxy-propyl)-4,7,10(carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane, DOTASA (1-(1-carboxy-2carboxy-ethyl)-4,7,10(carboxymethyl)1,4,7,10-tetraazacyclo-dodecane, or chelator (DOTA) [1,4,7,10 tetraazaacyclo-dodecane 1,4,7,10-tetra(acetic acid)] are useful radiopharmaceutical substances for targeting and treatment of brain tumors, especially gliomas. ... 02/22/07 - 20070041904 - Peptides whose uptake by cells is controllable A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, ... 02/22/07 - 20070041903 - Modified minigastrin analogs for oncology applications The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging ... 02/22/07 - 20070041902 - Somatostatin analogs with inhibitory activity to growth hormone release Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic Reagents, and methods of making and use thereof. ... 02/15/07 - 20070036720 - Radiolabelled metal transport protein as imaging agent A 99mcTc labeled metal transport protein, products and uses thereof in imaging and especially detecting the presence of high energy/iron uptake tissues such as a tumour within a mammalian body are provided. ... 02/08/07 - 20070031334 - Vitamin-targeted imaging agents for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M ... 02/08/07 - 20070031333 - Novel f-18 labeled annexin v, synthesis thereof, and use thereof A method for noninvasive measurement of apoptosis is described. The method includes the steps of labeling Annexin V with a positron emitter, injecting the labeled Annexin V into a target cell group, obtaining an image of the target cell group using a positron emission tomography scanner, and evaluating the image ... 02/08/07 - 20070031332 - Angiogenic agents from plant extracts, gallic acid, and derivatives An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid ... 01/11/07 - 20070009437 - Intracellular trapping of radionuclides by enzyme-mediated reduction Enzyme-mediated intracellular trapping of a radionuclide in a target cell is achieved by transfecting the target cell with a transgenic vector encoding a microbial hydrogenase expressible in the target cell and exposing the transfected target cell with a radionuclide. The transgenically expressed microbial hydrogenase catalyzes the reduction of the radionuclide. ... 01/11/07 - 20070009436 - Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto A nanoparticle radionuclide delivery system includes a radionuclide core, a non-radioactive inorganic layer encasing the radionuclide core to form an encased radionuclide, at least one coupling moiety, and at least one vector biomolecule specific to a target tissue. The coupling moiety includes a first reactive group bound to the non-radioactive ... 01/11/07 - 20070009435 - Compositions and methods for enhanced delivery to target sites A set of compounds that includes an active agent-labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a first oligomeric nucleotide or mimic thereof conjugated to a linker having a first moiety coupled with a diagnostic active agent. The pretargeting conjugate includes a second oligomeric nucleotide ... 12/28/06 - 20060292075 - Labelled glutamine and lysine analogues Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for ... 12/21/06 - 20060286033 - Targeting pulmonary epithelium using adrp This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is ... 12/21/06 - 20060286032 - A radiosotope-chitosan complex for treatment of prostate cancer Disclosed is a composition for treating prostate cancer. The composition for treating prostate cancer comprises as an effective ingredient a radioisotope-chitosan complex that includes a therapeutic radioisotope emitting beta radiation and chitosan. Also, the present invention discloses a kit for preparing the composition. When directly administered to a prostate cancer ... 12/07/06 - 20060275215 - Novel imaging agents The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic caspase-3 inhibitor labelled with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides pharmaceutical and radiopharmaceutical compositions comprising the imaging agents, together with kits for the preparation of ... 12/07/06 - 20060275214 - Methods of screening for anti-inflammatory drugs and use thereof The present invention relates to methods for screening small organic compounds capable of inhibiting the interactions of glycosaminoglycans with effector cell adhesion molecules. Specifically, the present invention provides a method for screening of small organic compounds, the compounds inhibit the interaction of heparin with L-selectin or P-selectin. The compounds identified ... 12/07/06 - 20060275213 - Tumor targeting agents and uses thereof This invention relates to novel tumor targeting motifs, units and agents, as well as tumor targeting peptides and analogues thereof. The targeting agents typically comprise at least one targeting motif, Aa-Bb-Cc, and at least one effector unit. The invention further relates to specific tumor targeting peptides, pharmaceutical and diagnostic composisitons ... 11/30/06 - 20060269481 - Cytotoxicity mediation of cells evidencing surface expression of cd63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic ... 11/30/06 - 20060269480 - Multi-triggered self-immolative dendritic compounds Novel self-immolative dendritic compounds which have a plurality of cleavable trigger units and hence can release a chemical moiety at their focal point upon a multi-triggering mechanism are disclosed. The novel self-immolative dendritic compounds are gated by a molecular logic gate, being either an AND or OR logic gate and ... 11/30/06 - 20060269479 - Amphiphilic polymers and methods of use thereof The present invention relates to amphiphilic polymers, and micelles and compositions comprising the same, and their use in a variety of biological settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes. ... 11/23/06 - 20060263295 - Chelators for radioactively labeled conjugates comprising a stabilizing sidechain The invention relates to a conjugate PT comprising (a) a peptide P and (b) a targeting moiety T; wherein the peptide P contains from 4 to 20 amino acid residues with optionally a single thiol moiety at the C— or N-terminus replacing one of these amino acid residues, and including ... 11/23/06 - 20060263294 - Tumor targeting agents and uses thereof This invention relates to novel tumor targeting motifs, units and agents, as well as tumor targeting peptides and ana-logues thereof. The targeting agents typically comprise at least one targeting motif, Aa-Bb-Cc, and at least one ef-fector unic. The invention further relates to specific tumor targeting peptides, pharmaceutical and diagnostic com-posisitons ... 11/16/06 - 20060257318 - Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual The present invention relates to the field of the in vitro diagnosis nosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. ... 11/02/06 - 20060246005 - Poly(peptide) as a chelator: methods of manufacture and uses Novel compositions for imaging that include (a) a polypeptide that includes two or more consecutive amino acids that will function to non-covalently bind valent metal ions and (2) a valent metal ion chelated to at least one of the two consecutive amino acids, are disclosed. Also disclosed are methods of ... 10/26/06 - 20060239914 - Gastrin releasing peptide compounds wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the ... 10/26/06 - 20060239913 - Peptide conjugate for magnetic resonance imaging The invention relates to new compounds and compositions for the imaging diagnostic of pathologies, namely for cardiovascular diseases, more precisely atherosclerosis disease. These compounds are contrast agents useful namely in the field of magnetic resonance imaging MRI and nuclear medicine. The compounds comprise a particular peptidic MMP inhibitor coupled with ... 10/19/06 - 20060233708 - Peptide antagonists of tgf-beta family members and therapeutic uses thereof This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of re-epithelialization ... 10/19/06 - 20060233707 - Process for producing an injectable medicament preparation The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance ... 10/19/06 - 20060233706 - Marked peptides having affinity for a phospholipid and uses in which the amino acids J are chosen independently of each other from natural amino acids, or derivatives thereof, in such a manner that at least 50% of them are polar residues chosen from Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Lys, Orn, Pro, Ser, Thr and Tyr, the ... 09/28/06 - 20060216237 - Inhibition of angiogenesis and tumor development by igfbp-4 The invention provides compositions comprising IGFBP-4 and methods for inhibiting angiogenesis and tumor development processes, and for treating angiogenesis-dependent conditions, using an insulin growth factor binding protein, IGFBP-4. ... 09/07/06 - 20060198786 - Glycopeptide compositions The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to ... 09/07/06 - 20060198785 - Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH, ... 08/31/06 - 20060193775 - Embedder compositions and methods for detecting and killing cells in acidic areas of tumors Embedder compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes an embedder peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the embedder peptide converts ... 08/31/06 - 20060193774 - Transporter compositions and methods for detecting and killing cells in acidic areas of tumors Improved transporter compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes a transporter peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the transporter peptide ... 08/31/06 - 20060193773 - Imaging agents The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. ... 08/24/06 - 20060188442 - X-ray guided drug delivery A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations ... 08/24/06 - 20060188441 - Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors Methods for labeling synthesis of radiolabeled gallium complex by microwave activation are provided. The resultant gallium-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). A method for imaging EGFR overexpression in tumors using PET is also provided. ... 08/17/06 - 20060182684 - Method for transporting a compound across the blood-brain barrier The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an ... 08/03/06 - 20060171885 - Skin or hair binding peptides The invention is directed to peptides. Specifically, the invention is directed to peptides which bind skin and do not bind hair. Alternatively, the invention is drawn to peptides which bind hair and do not bind skin. ... 07/27/06 - 20060165593 - Tc and re labeler radioactive glycosylated octreotide derivatives Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or ... 07/20/06 - 20060159620 - Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic.. Because of their anti-angiogenic potential, these molecules compounds are useful in the treatment of cancer by ... 07/20/06 - 20060159619 - Cell permeable nanoconjugates of shell-crosslinked knedel (sck) and peptide nucleic acids (pnas) with uniquely expressed or over-expressed mrna targeting sequences for early diagnosis and therapy of cancer A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds ... 06/29/06 - 20060140859 - Imaging agents for early detection and monitoring of cardiovascular plaque The present invention relates in part to a method of imaging cardiovascular plaque formation in a mammal comprising administering to the mammal an effective amount of 18F-2-fluorodeoxy-D-glucose and then detecting the 18F-2-fluorodeoxy-D-glucose. ... 06/29/06 - 20060140858 - Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds the targetable construct. The targetable construct comprises a carrier portion which comprises ... 06/08/06 - 20060120960 - Multivalent complexes, their production and method of use Multivalent complexes will be described, as well as their production and method of use. ... 05/18/06 - 20060104900 - Polymer precursors of radiolabeled compounds, and methods of making and using the same One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds. ... 05/04/06 - 20060093554 - Galenical formulations This invention describes new galenical formulations that contain paramagnetic and diamagnetic perfluoroalkyl-containing compounds. The new formulations are suitable as contrast media for nuclear spin tomography. ... 04/20/06 - 20060083685 - Opioid metallopeptide compositions and methods Metallopeptides and metallopeptide combinatorial libraries specific for opioid receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed in a biologically active configuration specific for one ... 04/20/06 - 20060083684 - Method of radio-labelling biomolecules A method of radio-labelling a biomolecule comprising contacting the biomolecule with a source of radionuclide, such as technetium, in the presence of a weak transfer ligand and optionally subsequently passing the mixture through a size-exclusion filtration process. Also claimed are kits comprising such novel compositions, especially lactoferrin coupled to chemotherapeutic ... 03/30/06 - 20060067886 - Gastrin receptor-avid peptide conjugates A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject ... 03/16/06 - 20060057064 - Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient A compound binding to leukocytes, which comprises Met-Leu-Phe or Nle-Leu-Phe serving as the leukocyte-binding site of a formyl peptide receptor (FPR), a binding part comprising Ser or Thr elevating the binding ratios to monocytes and lymphocytes in all leukocytes, a group which can be labeled with a radioactive metal or ... 03/16/06 - 20060057063 - Medicaments A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and ... 02/23/06 - 20060039861 - Peptide-based multimeric targeted contrast agents Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents. ... 02/16/06 - 20060034760 - Radiopharmaceutical formulations Radiopharmaceutical compounds are disclosed having a radionuclide chelating moiety and a targeting ligand, and optionally a linker. Formulations of compositions useful for making the radiopharmaceutical compounds contain a chelating ligand, a reducing agent, an exchange ligand and a stabilizer. ... 02/09/06 - 20060029545 - Radiolabeled annexins Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided. ... 02/09/06 - 20060029544 - Receptor-binding cyclic peptides and methods of use The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a ... 01/26/06 - 20060018831 - Tf binding agent and use thereof This invention relates to novel compounds, which bind to tissue factor and the use thereof for diagnostic and/or therapeutic purposes. ... 01/26/06 - 20060018830 - Gastrin releasing peptide compounds wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the ... 12/29/05 - 20050287067 - Compounds of the inventions of guanylyl cyclase c Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed. ... 12/22/05 - 20050281741 - Receptor-avid exogenous optical contrast and therapeutic agents Cyanine and Indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive ... 12/22/05 - 20050281740 - Imaging damaged lung tissue The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find ... 12/22/05 - 20050281739 - Imaging damaged lung tissue using compositions The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find ... 12/08/05 - 20050271589 - B-superfamily conotoxins The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. ... 12/08/05 - 20050271588 - Liposome targeting of matrix metalloproteinase inhibitors The present invention relates to targeted cancer therapy, and concerns specifically the use of small matrix metalloproteinase inhibitors in improving targeting of liposomes to cancer cells, and in enhancing the uptake thereof to such cells. The invention thus provides a method for treating cancer, as well as a method for ... 12/08/05 - 20050271587 - Alpha-fetoprotein peptides and uses thereof The subject invention addresses the need for methods of treatment and prevention of breast cancer, and other cancers, by providing a peptide of eight to twenty amino acids in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO:6: EMTPVNPG. The peptides may be linear, but ... 11/10/05 - 20050249664 - Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis The present invention relates to biochemical methods for determining reverse cholesterol transport. Specifically, the rates of the two arms of reverse cholesterol transport (HDL or first arm and post-HDL or second arm) are obtained by measuring the flow of unlabeled cholesterol from tissues into plasma HDL and from plasma HDL ... 11/03/05 - 20050244334 - Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders A pharmaceutical composition that includes a peptide of formula Y-(X-aa)-Z. (X-aa) is generally an amino acid sequence selected from -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile-, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-, and -Thr-Leu-Phe-Leu-Ala-Arg-. And Y is generally an amino terminal modifying group selected from an amino acid, a N-acylated amino acid, a peptide, a N-acylated peptide, and hydrogen. ... 10/27/05 - 20050238579 - Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level ... 10/13/05 - 20050226813 - Labelled somatostatin analogs backbone cyclized through metal complexation Novel diagnostic and therapeutic peptides disclosed herein are somatostatin analogs backbone cyclized through metal complexation, and having improved somatostatin receptor subtype affinity and selectivity. These backbone cyclized peptide analogs possess unique and superior properties over other analogs, including chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Pharmaceutical compositions ... 10/06/05 - 20050220706 - Erbb-2 receptor targeting peptide The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was ... 09/29/05 - 20050214213 - Cone snail peptides The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention ... 09/15/05 - 20050201934 - Binding peptides for carcinoembryonic antigen (cea) The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding CEA, which is overexpressed in adenocarcinomas of endodermally ... 09/08/05 - 20050196340 - Use of a vegf antagonist in combination with radiation therapy Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, in combination with radiation therapy and/or a therapeutic radiopharmaceutical. ... 09/01/05 - 20050191241 - Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in ... 09/01/05 - 20050191240 - Labeled neurotensin derivatives Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes. ... 07/28/05 - 20050163710 - Gastrin receptor-avid peptide conjugates A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject ... 06/02/05 - 20050118100 - Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin target imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) ... ### FreshPatents.com Support |